Eloralintide (LY3841136) discussion from discovery to potential use

Yeah, plenty here are probably watching the early eloralintide data and wondering how soon it reaches the research market. I picked up some cagrilintide earlier in my own GLP-1 run in case I hit a plateau short of goal, but it feels like it might already be outdated before I even use it.

Appreciate the link. Eloralintide has me interested. Right now I run tirzepatide and retatrutide for maintenance. Cagrilintide gave me nonstop headaches that cleared up once I quit. Eloralintide plus retatrutide feels like it could be a strong pair, and I expect maintenance doses of both would stay modest. Looking forward to testing it.

Cagrilintide works well for me, so eloralintide should be even better. Hope it arrives quickly.

I will switch my research subject straight from cagrilintide to eloralintide the moment it is obtainable.

Wondering what the cost will look like. Cagrilintide already runs high, so this one will probably cost more.

This peptide looks more involved than retatrutide or tirzepatide because of several non-standard amino acids, a distinctive ring structure at one end, and the usual lipid attachment for longer action. That will make synthesis tougher. Hopefully the Chinese labs can still handle it. Otherwise the profile looks solid: fewer sides and better results than cagrilintide. Should pair well with retatrutide for harder cases of obesity.

Still cheaper than the eventual branded version, so it remains a good deal.